key: cord-0747056-9oe4plcf
authors: Foster, Charles S.P.; Madden, Mathew; Chan, Raymond; Agapiou, David; Bull, Rowena A.; Rawlinson, William D.; Van Hal, Sebastiaan J.
title: SARS-CoV-2 N-gene mutation leading to Xpert Xpress SARS-CoV-2 assay instability
date: 2022-04-16
journal: Pathology
DOI: 10.1016/j.pathol.2022.02.001
sha: 7726a876608a7f0b4d65fa46f6c54de996a1be92
doc_id: 747056
cord_uid: 9oe4plcf

nan

Sir, Real-time reverse transcription polymerase chain reaction (RT-PCR) assays have formed the backbone of COVID-19 diagnosis since the start of the SARS-CoV-2 pandemic. Assay performances have remained relatively stable over the course of the pandemic to date, but any genomic variants in the primer binding or probe regions of assays have the potential to compromise performance. One notable example is the spike protein H69/70del mutation, associated with the emergence of the alpha variant (B.1.1.7). 1 H69/70del results in false negative S-gene results in the Applied Biosystems TaqPath COVID-19 assay (ThermoFisher Scientific, USA), but the two other gene targets of the assay are not affected. This altered assay performance became a proxy for detection of the alpha variant. 1 Surveillance for mutations causing diagnostic assay failures for specific gene targets is crucial, especially if only one gene target is used in a particular assay.

There have been relatively few COVID-19 cases in Australia relative to global case numbers, but there is currently (1) a sustained outbreak of COVID-19 infections stemming from community transmission of the delta variant of concern (VOC) in June (Winter) 2021, and (2) rising case numbers of the omicron VOC since early December 2021. The Xpert Xpress SARS-CoV-2 assay ('GX'; Cepheid, USA) is one of several diagnostic assays currently used for detection of SARS-CoV-2 in Australia and globally. The GX assay has two targets within the envelope (E) and nucleocapsid (N) genes of SARS-CoV-2. If a sample is positive, the expected behaviour is for both gene targets to be detected with similar cycle threshold (Ct) values. 1 A change in the performance of the GX assay was recently observed across multiple assay cartridges from different cartridge lots, with large differences in cycle threshold (Ct) values between the E and N gene targets in a subset of delta SARS-CoV-2 samples. Samples were classified as possessing an altered GX profile (GX alt ) if there was a >3 Ct value difference between the E and N gene targets of the assay. A single category change to presumptive positive was adopted when a sample was E-gene positive (Ct value >30) but was N-gene negative.

The altered GX profile was first observed in August of 2021 in 9.5% (10/105) of cases, increasing to 20% (18/88) and 15% (3/20) of cases in September and October, respectively. Retrospective analysis of all positive cases from July 2021 confirmed that 0% (0/110) of cases exhibited the altered GX profile (GX alt ). Although the altered GX profile was defined as any sample with a greater than three Ct value difference between E-gene and N-gene targets, the differential was often far greater (median 10 Ct, IQR 9e11 Ct). Throughout the period of testing, no false negatives were observed.

Whole genome sequencing of isolates was undertaken as part of routine genomic sequencing, as previously described. 2 A candidate causative SNP for the GX alt profile was identified at genomic position 29179 of the SARS-CoV-2 genome (G29179T) through comparative analyses. This SNP was not observed in any non-GX alt samples.

Most commercial assays use closed-source, proprietary primer sequences. However, definitively linking SNPs to altered assay performance requires knowing the primer sequences, or precise target locations on the reference genome. Accordingly, we cloned the GX assay primers into a pcDNA3.1V5 His plasmid backbone (#K480001; Thermo-Fisher Scientific Australia), then sequenced purified clone products using Sanger sequencing. Thus, we confirmed that the G29179T point mutation is located 5 nt upstream from the 3 0 end of the N-gene target region of the GX assay (Fig. 1) . In correspondence, Cepheid agreed that 'the data appear to support this (altered assay performance)' (personal communication).

At the time of carrying out this study, the G29179T SNP had not yet been linked to assay instability. However, during the editorial process, three studies from Western Australia, South Korea, and the United States of America have found that the G29179T SNP leads to N-gene target detection failure in the GX assay, 3e5 strongly and independently supporting our findings in the present manuscript. Instability of the GX assay caused by different point mutations has also been observed previously. For example, previously described mutations have resulted in GX N-target failure, with explanation centred on the primers/probes closely resembling the Centers for Disease Control and Prevention (CDC) primer and probe set. 6e10 Given the impact of G29179T on the GX assay, and the assay's global popularity for diagnostics, we queried the global phylogeny of SARS-CoV-2 (https://hgdownload.soe. ucsc.edu/goldenPath/wuhCor1/UShER_SARS-CoV-2/, 20 December 2021) to determine the global spread and abundance of G29179T. By querying the phylogeny using matUtils, 11 we determined that 12,481 of 3,152,290 (0.4%) sequences in the global alignment from 27 countries (earliest occurrence 15 March 2020) contained the G29179T mutation. Given that the phylogeny is not exhaustive with respect to global sequencing efforts (for example by not including any sequences that are only available on GISAID; https:// www.gisaid.org/), the true number of samples with G29179T is likely higher. Samples with G29179T were not monophyletic, emerging independently in multiple lineages, suggesting convergent acquisition of G29179T. The G29179T mutation is most prevalent in delta genomes, and no omicron samples have yet acquired the G29179T mutation. However, the independent acquisition of G29179T in a wide range of lineages suggests that omicron samples may also be affected over time.

Our analysis cannot suggest whether the repeated evolution of G29179T is adaptive or neutral, but, regardless, the mutation is clearly important for molecular diagnostics. Given the global distribution of G29179T, and independent confirmation of its negative impact on the GX assay in three different countries, 3e5 the global performance of the GX assay and other assays that target the N-gene [e.g., Mira-Mic SARS-CoV-2 (Bio Molecular Systems, Australia) and BD Max COVID-19 (BD Life Sciences, USA)] is likely to be affected. 12 Consequently, obtaining a positive result is reliant on the stability of the alternative target(s) of these assays, with pooling of samples potentially leading to incremental performance instability. Clinicians should be aware of this emerging problem in diagnosing delta SARS-CoV-2 and that ongoing assay performance monitoring is critical in the setting of rapid viral evolution.

Conflicts of interest and source of funding: The authors state that there are no conflicts of interest to disclose. Centers for Disease Control and Prevention (CDC) primer and probe targets of the nucleocapsid gene of SARS-CoV-2 and current identified mutations within these regions. The N2 target region for diagnostic assays of the nucleoprotein gene is depicted in pink, with genome positions numbered according to the reference genome (Wuhan-HU-1; NC_045512.2). The primers are shown for the Xpert Xpress SARS-CoV-2 assay (GX; Cepheid USA), as determined through molecular cloning. The GX primer targets are very similar to the CDC published PCR primer set, 6,10 so we show the CDC probe location. The location of the synonymous mutation on which the present study focuses (29179: G/T) is highlighted by the yellow box and underlined, five nucleotides upstream of the 3 0 end of the GX forward primer. Previously described nucleocapsid mutation locations are shown by the red boxes, within the probe (29197: C/T; 29200: C/T/A) and reverse primer (29227: G/T) regions, and have resulted in GX assay failure and instability, respectively. 3e5,7e9

Emergence of SARS-CoV-2 B.1.1.7 Lineage -United States

Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis

Single-point mutations in the N gene of SARS-CoV-2 adversely impact detection by a commercial dual target diagnostic assay

Prevalence of a single-nucleotide variant of SARS-CoV-2 in Korea and its impact on the diagnostic sensitivity of the Xpert Xpress SARS-CoV-2 assay

SARS-CoV-2 N gene mutations impact detection by clinical molecular diagnostics: reports in two cities in the United States

Multiplex real-time reverse transcription PCR for influenza A virus, influenza B virus, and severe acute respiratory syndrome coronavirus 2

SARS-CoV-2 samples may escape detection because of a single point mutation in the N gene

Lack of N2-gene amplification on the Cepheid Xpert Xpress SARS-CoV-2 assay and potential novel causative mutations: A case series from

A novel point mutation in the N gene of SARS-CoV-2 may affect the detection of the virus by reverse transcription-quantitative PCR

US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2

A daily-updated database and tools for comprehensive SARS-CoV-2 mutation-annotated trees

Understanding false positives and the detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and BD MAX SARS-CoV-2 assays